{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005322","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2026-08-06T20:20:20+00:00","discovered_at":"2026-08-06T20:21:00.308972+00:00","generated_at":"2026-08-06T20:21:44.958733+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Profound Medical Q2 revenue $2.5M (+12% YoY); net loss improves 39% to $9.5M; reiterates FY2026 guidance of $25M","bullets":["Revenue $2.5M, up 12% YoY; $3.1M of TULSA shipments shifted to Q3 due to logistics, resolved.","Net loss $9.5M ($0.26/share) vs $15.7M ($0.52/share) in Q2 2025, a 39% improvement.","Gross margin 78% (up from 73%); operating expenses down 16% to $13.0M.","Reiterates FY2026 revenue guidance of $25.0M (56% YoY growth) and gross margin ≥70%.","TULSA-PRO installed base 84; payer coverage expanded by 18.3M lives; first employer health plans list TULSA."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005322","json":"https://secwatch.observer/filing/0001171843-26-005322.json","markdown":"https://secwatch.observer/filing/0001171843-26-005322.md","text":"https://secwatch.observer/filing/0001171843-26-005322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/0001171843-26-005322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/f8k_080626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:21:44.958733+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}